EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Mark P Hamilton, David B Miklos, Ash A Alizadeh

New England Journal of Medicine · 2024

DOI: 10.1056/nejmc2408733 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Mark P Hamilton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Stanford, CA arasha@stanford.edu. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, T-Cell, Neoplasms, Second Primary, Clonal Hematopoiesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, T-CellNeoplasms, Second PrimaryClonal HematopoiesisLymphoma, B-CellAntineoplastic Agents, ImmunologicalHumansReceptors, Chimeric AntigenRiskHerpesvirus 4, HumanBiological ProductsCytokine Release Syndrome

Substanzen

Receptors, Chimeric Antigenaxicabtagene ciloleucelAntineoplastic Agents, ImmunologicalBiological Products

Autor:innen und Institutionen

  • Stanford University School of Medicine, Stanford, CA arasha@stanford.edu.

Zitieren

APA

Hamilton, M. P., Miklos, D. B., & Alizadeh, A. A. (2024). Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejmc2408733

Vancouver

Hamilton MP, Miklos DB, Alizadeh AA. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. New England Journal of Medicine. 2024. doi:10.1056/nejmc2408733

BibTeX
@article{Hamilton2024,
  author = {Hamilton, Mark P and Miklos, David B and Alizadeh, Ash A},
  title = {Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejmc2408733}
}
Kostenlos starten →